Overview

Dapagliflozin in STEMI Randomized Clinical Trial

Status:
Not yet recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.

Phase:

Phase 3

Details

Lead Sponsor:

Ottawa Heart Institute Research Corporation

Treatments:

Dapagliflozin